Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
carbapenem resistant Enterobacterales
cefiderocol
extended spectrum beta
gram
lactamase producing (ESBL)
multidrug resistant
negative bacteria
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
09 04 2022
09 04 2022
Historique:
received:
16
02
2021
pubmed:
8
9
2021
medline:
13
4
2022
entrez:
7
9
2021
Statut:
ppublish
Résumé
Cefiderocol is a novel injectable siderophore cephalosporin that hijacks the bacterial iron transport machinery to facilitate cell entry and achieve high periplasmic concentrations. It has broad in vitro activity against gram-negative bacteria, including multidrug-resistant (MDR) organisms such as carbapenem-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii. It was approved by the US Food and Drug Administration for the treatment of complicated urinary tract infections and nosocomial pneumonia based on clinical trials that demonstrated noninferiority to comparators. In this review, we summarize the available in vitro and clinical data, including recent evidence from 2 phase 3 clinical trials (APEKS-NP and CREDIBLE-CR), and discuss the place of cefiderocol in the clinician's armamentarium against MDR gram-negative infections.
Identifiants
pubmed: 34492098
pii: 6366026
doi: 10.1093/cid/ciab757
pmc: PMC9989360
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Cephalosporins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1303-1312Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIAID NIH HHS
ID : R25 AI147369
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
J Antimicrob Chemother. 2019 Jul 1;74(7):1971-1974
pubmed: 31220260
Lancet Infect Dis. 2018 Dec;18(12):1319-1328
pubmed: 30509675
J Antimicrob Chemother. 2020 Jul 1;75(7):1840-1849
pubmed: 32277821
Int J Antimicrob Agents. 2019 Apr;53(4):456-466
pubmed: 30471402
Antimicrob Agents Chemother. 2021 Feb 17;65(3):
pubmed: 33257454
J Clin Pharmacol. 2017 May;57(5):584-591
pubmed: 27874971
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29311072
Antimicrob Agents Chemother. 2016 Dec 27;61(1):
pubmed: 27795374
Infect Dis Ther. 2020 Mar;9(1):17-40
pubmed: 32072491
Antimicrob Agents Chemother. 2019 Oct 7;:
pubmed: 31591126
Antimicrob Agents Chemother. 2015 Nov 16;60(2):729-34
pubmed: 26574013
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30420477
J Clin Pharmacol. 2019 Jul;59(7):958-967
pubmed: 30730562
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29061741
Clin Infect Dis. 2021 Jun 1;72(11):2021-2024
pubmed: 32941593
Lancet Infect Dis. 2021 Feb;21(2):226-240
pubmed: 33058795
Open Forum Infect Dis. 2020 May 21;7(6):ofaa185
pubmed: 32548207
Antimicrob Agents Chemother. 2017 Jun 27;61(7):
pubmed: 28438934
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S538-S543
pubmed: 31724047
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 32727829
Int J Antimicrob Agents. 2019 Feb;53(2):177-184
pubmed: 30395986
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S559-S564
pubmed: 31724048
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28630178
Antimicrob Agents Chemother. 2020 Nov 17;64(12):
pubmed: 32958717
J Glob Antimicrob Resist. 2020 Dec;23:292-296
pubmed: 33065329
Antimicrob Agents Chemother. 2019 Aug 23;63(9):
pubmed: 31262762
Open Forum Infect Dis. 2020 May 05;7(5):ofaa150
pubmed: 32494581
Pharmacy (Basel). 2019 Jul 29;7(3):
pubmed: 31362351
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28848004
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29038272
Infect Drug Resist. 2020 Dec 29;13:4697-4711
pubmed: 33402840
Antimicrob Agents Chemother. 2018 Dec 21;63(1):
pubmed: 30323050
Drugs. 2019 Feb;79(3):271-289
pubmed: 30712199
Clin Infect Dis. 2021 Jun 15;72(12):e1103-e1111
pubmed: 33393598
Lancet Infect Dis. 2021 Feb;21(2):213-225
pubmed: 33058798
J Glob Antimicrob Resist. 2020 Sep;22:738-741
pubmed: 32702396